Cargando…
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody
BACKGROUND: Selective neutralization of the IL21/IL21R signaling pathway is a promising approach for the treatment of a variety of autoimmune diseases. Ab-01 is a human neutralizing anti-IL21R antibody. In order to ensure that the activities of Ab-01 are restricted to neutralization even under in vi...
Autores principales: | Guo, Yongjing, Hill, Andrew A, Ramsey, Renee C, Immermann, Frederick W, Corcoran, Christopher, Young, Deborah, LaVallie, Edward R, Ryan, Mark, Bechard, Theresa, Pfeifer, Richard, Warner, Garvin, Bologna, Marcia, Bloom, Laird, O'Toole, Margot |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896924/ https://www.ncbi.nlm.nih.gov/pubmed/20504348 http://dx.doi.org/10.1186/1479-5876-8-50 |
Ejemplares similares
-
Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood
por: Arai, Maya, et al.
Publicado: (2010) -
Publication trends in the medical informatics literature: 20 years of "Medical Informatics" in MeSH
por: DeShazo, Jonathan P, et al.
Publicado: (2009) -
Production of lignin based insoluble polymers (anionic hydrogels) by C. versicolor
por: Brzonova, Ivana, et al.
Publicado: (2017) -
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
por: Rampuria, Pragya, et al.
Publicado: (2023) -
Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys
por: Vugmeyster, Yulia, et al.
Publicado: (2010)